Accessibility

BIOTECHNOLOGY / PHARMA R&D

DCU has invested heavily in its life science research, specialist facilities and equipment making DCU an attractive place for pharmaceutical and biotechnology companies to enter into mitigated-risk collaborative research. DCU’s expertise can be leveraged to meet the technical needs of life science companies from early stage technology development, through proof of concept validation, clinical evaluation to market launch.
Detailed information regarding DCU’s life science expertise is available here

National Institute for Cellular Biotechnology NICB logo on Invent DCU website

National Institute for Cellular Biotechnology (NICB)
The NICB is a multidisciplinary centre of research in fundamental and applied Cellular Biotechnology, Molecular Cell Biology, Ocular diseases and Biological Chemistry. It includes a multidisciplinary team of Cell and Molecular Biologists, Biotechnologists, Chemists and Computer Scientists.
Its major research focus areas include:

Cancer Therapeutics and Pharmacology
Multiple Myeloma Research
Monoclonal Antibodies to Study Cancer
Brain Cancer Research
Serum Biomarkers for Cancer
Stem Cell Therapy and Tissue Engineering
Cell & Molecular Biology Underlying Cellular Systems for Biopharmaceutical Production
DNA viruses & Regulation of Protein Synthesis

LICENSING OPPORTUNITIES
 
Biomarker Test for Predicting Response in Multiple Myeloma Patients

Dublin City University in collaboration with a Consultant Haematologist at the Mater Hospital Dublin have developed a biomarker based test for predicting response to therapy in individuals with Multiple Myeloma. We have discovered a panel of novel biomarkers which can predict a patient’s response to thalidomide therapy with an accuracy of approximately 84%.
Multiple Myeloma Licensing Opportunity (PDF)

Novel Panel of Breast Cancer Biomarkers
The Proteomics group at the NICB have discovered a novel panel of biomarkers that will significantly improve the method of measuring the response of an individual with breast cancer to various therapies and of diagnosing the recurrence of breast cancer.
Breast Cancer Licensing Opportunity (PDF)

microRNAs in Cell Lines for Biopharmaceutical Production
The majority of biopharmaceuticals are manufactured using Chinese Hamster Ovary (CHO) cells which are grown in large bioreactors. Although the efficiency of CHO-based processes has improved in the last two decades, they are considerably less productive than bacterial or yeast systems. DCU has developed technology that can offer significant enhancements in process efficiencies.                                     
microRNA Licensing Opportunity (PDF)


Molecular Therapautics for Cancer Ireland logo on Invent DCU website

Molecular Therapeutics for Cancer, Ireland (MTCI)
Molecular Therapeutics for Cancer, Ireland (MTCI) is a Science Foundation Ireland-funded Strategic Research Cluster which aims to discover and develop new anti-cancer drugs and is hosted at the NICB.
There is an urgent need for improved drug treatments for cancer, which is emerging as the leading cause of mortality in Ireland and other western countries. Traditional cancer chemotherapy has resulted in improved outcomes for some types of cancer, but remains a generally unsatisfactory form of treatment, with low rates of cure, and prominent side-effects.

For further information on DCU’s Life Science research and industry engagement, contact:
Ms. Emma O’Neill, Business Development Manager, Life Sciences, DCU    
Email: emma.oneill@invent.dcu.ie Tel: 00 353 1 700 7741